MCID: MYC005
MIFTS: 45

Myocardial Stunning

Categories: Cardiovascular diseases

Aliases & Classifications for Myocardial Stunning

MalaCards integrated aliases for Myocardial Stunning:

Name: Myocardial Stunning 12 54 44 15 70

Classifications:



External Ids:

Disease Ontology 12 DOID:9767
MeSH 44 D017682
UMLS 70 C0206146

Summaries for Myocardial Stunning

MalaCards based summary : Myocardial Stunning is related to ventricular fibrillation, paroxysmal familial, 1 and intermediate coronary syndrome, and has symptoms including polydipsia, fatigue and cyanosis. An important gene associated with Myocardial Stunning is SLC9A1 (Solute Carrier Family 9 Member A1), and among its related pathways/superpathways are Peptide ligand-binding receptors and Oxytocin signaling pathway. The drugs Metoprolol and Chlorhexidine have been mentioned in the context of this disorder. Affiliated tissues include heart, endothelial and neutrophil, and related phenotypes are Decreased substrate adherent cell growth and Decreased substrate adherent cell growth

Wikipedia : 73 Myocardial stunning or transient post-ischemic myocardial dysfunction is a state of mechanical cardiac... more...

Related Diseases for Myocardial Stunning

Diseases related to Myocardial Stunning via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 145)
# Related Disease Score Top Affiliating Genes
1 ventricular fibrillation, paroxysmal familial, 1 30.6 TNNT2 SLC9A1 KNG1 KCNJ5
2 intermediate coronary syndrome 30.5 TNNT2 TNNI3 SERPINC1 ACE
3 cardiac arrest 30.5 TNNT2 TNNI3 ACE
4 mitral valve insufficiency 30.3 TNNT2 TNNI3 ACE
5 arteries, anomalies of 30.3 TNNI3 EDN1 AGTR1 ACE
6 acute myocardial infarction 30.0 TNNT2 TNNI3 SERPINC1 EDN1 AGTR1 ACE
7 coronary artery vasospasm 30.0 TNNI3 KNG1 EDN1 AHSP ACE
8 hypertrophic cardiomyopathy 29.7 TNNT2 TNNI3 KCNJ5 EDN1 AGTR1 ACE
9 pulmonary edema 29.7 TNNT2 TNNI3 SERPINC1 KNG1 EDN1 AGTR1
10 chronic kidney disease 29.5 TNNT2 TNNI3 SOD1 EDN1 AGTR1 ACE
11 pulmonary hypertension 29.2 SERPINC1 EDN1 AGTR1 ACE
12 congestive heart failure 29.1 TNNT2 TNNI3 KNG1 EDN1 AGTR1 ADORA1
13 cardiovascular system disease 29.1 SOD3 SOD1 SERPINC1 KNG1 EDN1 AGTR2
14 ischemia 28.7 SOD1 SLC9A1 KNG1 KCNJ5 EDN1 ADORA3
15 myocardial infarction 28.5 TNNT2 TNNI3 SOD3 SERPINC1 KNG1 KCNJ5
16 lipoprotein quantitative trait locus 28.5 TNNT2 TNNI3 SOD3 SLC9A1 KNG1 KCNJ5
17 coronary stenosis 10.5
18 atrial standstill 1 10.5
19 cardiogenic shock 10.4
20 broken heart syndrome 10.4
21 rheumatic myocarditis 10.4 TNNT2 TNNI3
22 platelet aggregation, spontaneous 10.4 SOD1 SERPINC1
23 cerebral arteritis 10.3 SERPINC1 EDN1
24 meningitis and encephalitis 10.3 SOD1 CAT
25 meningococcal infection 10.3 SOD1 AGTR1
26 malignant renovascular hypertension 10.3 EDN1 AGTR1
27 plantar fascial fibromatosis 10.3 AGTR2 AGTR1
28 toxic myocarditis 10.2 TNNI3 ACE
29 central retinal artery occlusion 10.2 SERPINC1 EDN1
30 inferior myocardial infarction 10.2 TNNI3 ACE
31 volkmann contracture 10.2
32 kidney papillary necrosis 10.2 EDN1 ACE
33 cholesterol embolism 10.2 SERPINC1 ACE
34 idiopathic edema 10.2 EDN1 ACE
35 perinephritis 10.2 EDN1 ACE
36 intracranial embolism 10.1 SERPINC1 ACE
37 hellp syndrome 10.1 SERPINC1 EDN1 AHSP
38 pulmonary valve insufficiency 10.1 EDN1 ACE
39 constrictive pericarditis 10.1 TNNI3 ACE
40 urinary tract infection 10.1 CAT ACE
41 familial hyperaldosteronism 10.1 KCNJ5 AGTR1
42 friedreich ataxia 10.1 TNNT2 TNNI3 SOD1 AGTR1
43 aldosterone-producing adenoma 10.1 KCNJ5 AGTR2 AGTR1
44 silent myocardial infarction 10.1 TNNT2 TNNI3 ACE
45 hypertensive retinopathy 10.1 AGTR1 ACE
46 left bundle branch hemiblock 10.1 TNNT2 TNNI3 ACE
47 acute myocarditis 10.1 TNNT2 TNNI3 ACE
48 pericardium disease 10.1 TNNT2 TNNI3 ACE
49 tricuspid valve insufficiency 10.1 TNNI3 EDN1 ACE
50 eclampsia 10.1 SERPINC1 EDN1 ACE

Graphical network of the top 20 diseases related to Myocardial Stunning:



Diseases related to Myocardial Stunning

Symptoms & Phenotypes for Myocardial Stunning

UMLS symptoms related to Myocardial Stunning:


polydipsia; fatigue; cyanosis; edema; chills; asthenia; signs and symptoms; signs and symptoms, digestive; hot flushes; signs and symptoms, respiratory; oral manifestations; eye manifestations; urological manifestations; hypertriglyceridemic waist; body temperature changes; skin manifestations; renal colic; mobility limitation; prodromal symptoms; medically unexplained symptoms

GenomeRNAi Phenotypes related to Myocardial Stunning according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased substrate adherent cell growth GR00193-A-1 9.17 ADORA1 ADORA2B ADORA3 AGTR1 AGTR2
2 Decreased substrate adherent cell growth GR00193-A-3 9.17 ADORA1 ADORA2B

MGI Mouse Phenotypes related to Myocardial Stunning:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.22 ACE ADORA1 ADORA2B ADORA3 AGTR1 AGTR2
2 cardiovascular system MP:0005385 10.21 ACE ADORA1 ADORA2B ADORA3 AGTR1 AGTR2
3 mortality/aging MP:0010768 10.07 ACE ADORA1 ADORA2B AGTR1 AGTR2 CAT
4 muscle MP:0005369 9.7 AGTR2 EDN1 SERPINC1 SOD1 SOD3 TNNI3
5 nervous system MP:0003631 9.7 ACE ADORA1 ADORA2B AGTR1 AGTR2 EDN1
6 renal/urinary system MP:0005367 9.23 ACE ADORA1 ADORA2B ADORA3 AGTR1 AGTR2

Drugs & Therapeutics for Myocardial Stunning

Drugs for Myocardial Stunning (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 66)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Metoprolol Approved, Investigational Phase 4 51384-51-1, 37350-58-6 4171
2
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
3
Ticagrelor Approved Phase 4 274693-27-5 9871419
4
Atorvastatin Approved Phase 4 134523-00-5 60823
5
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
6
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
7
Nutmeg Approved Phase 4
8
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 15589840
9
Methylcobalamin Approved, Investigational Phase 4 13422-55-4
10
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
11
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
12
Cobalamin Experimental Phase 4 13408-78-1 6857388
13
Simendan Investigational Phase 4 131741-08-7
14 Calcium, Dietary Phase 4
15 Antihypertensive Agents Phase 4
16 Rosuvastatin Calcium Phase 4 147098-20-2
17 Anticholesteremic Agents Phase 4
18 Fibrinolytic Agents Phase 4
19 Anti-Arrhythmia Agents Phase 4
20 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
21 Antimetabolites Phase 4
22 Adrenergic beta-Antagonists Phase 4
23 Antirheumatic Agents Phase 4
24 Purinergic P2Y Receptor Antagonists Phase 4
25 Mace Phase 4
26 Chlorhexidine gluconate Phase 4
27 Adrenergic Antagonists Phase 4
28 Hypolipidemic Agents Phase 4
29 Anti-Inflammatory Agents Phase 4
30 Adrenergic beta-1 Receptor Antagonists Phase 4
31 Platelet Aggregation Inhibitors Phase 4
32 Cyclooxygenase Inhibitors Phase 4
33 Adrenergic Agents Phase 4
34 Neurotransmitter Agents Phase 4
35 Lipid Regulating Agents Phase 4
36 calcium channel blockers Phase 4
37 Antipyretics Phase 4
38 Analgesics, Non-Narcotic Phase 4
39 Anti-Inflammatory Agents, Non-Steroidal Phase 4
40 Analgesics Phase 4
41 Sympatholytics Phase 4
42 Pharmaceutical Solutions Phase 4
43 Vasodilator Agents Phase 4
44 Micronutrients Phase 4
45 Cardioplegic Solutions Phase 4
46 Trace Elements Phase 4
47 Vitamin B9 Phase 4
48 Nutrients Phase 4
49 Vitamin B12 Phase 4
50 Cardiotonic Agents Phase 4

Interventional clinical trials:

(show all 12)
# Name Status NCT ID Phase Drugs
1 The Success of Opening Single CTO Lesions to Improve Myocardial Viability Study (SOS-comedy) Completed NCT02767401 Phase 4 aspirin, clopidogrel, ticagrelor, atorvastatin, rosuvastatin, betaloc
2 Intracoronary Administration of Levosimendan in Cardiac Surgery Patients Terminated NCT01500785 Phase 4 levosimendan;Vitamin B 12
3 Ranolazine Myocardial Protection in Complete Coronary Artery Bypass Grafting: A Randomized-controlled Trial Withdrawn NCT02687269 Phase 4 Ranolazine;Placebo
4 A Randomized Placebo Controlled Single Center Phase 1 Study to Evaluate Safety and Efficacy of IV Diazoxide as an Additive to Hyperkalemic Cardioplegia in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass Not yet recruiting NCT04830982 Phase 1 IV Diazoxide
5 Rate of Left Ventricular Systolic Function's Recuperation After Cardiac Surgery With Extracorporeal Circulation. Unknown status NCT02770183
6 Serial Echocardiography After Subarachnoid Hemorrhage (S.E.A.S.) Unknown status NCT00123695
7 Myocardial Stunning During Hemodialysis: Role of Dialyste Calcium Concentration Completed NCT02545426
8 Magnetic Resonance Technique in the Assessment of Exercise-induced Long- and Short-Term Changes in Cardiac Function and Morphology Completed NCT01179802
9 Prediction of Left Ventricular Function Changes Using Low Dose Dobutamine Gated SPECT in Patients Referred for Viability Assessment: The DOGS (DObutamine Gated Spect)Study. Completed NCT00213746
10 Cardiomyocyte Injury Following Acute Ischemic Stroke Recruiting NCT03892226
11 STAMI- Stunning in Takotsubo Versus Acute Myocardial Infarction Recruiting NCT04448639
12 Immunomodulatory Biomimetic Device to Treat Myocardial Stunning in End-stage Renal Disease Patients (ERSD) Recruiting NCT03539861

Search NIH Clinical Center for Myocardial Stunning

Cochrane evidence based reviews: myocardial stunning

Genetic Tests for Myocardial Stunning

Anatomical Context for Myocardial Stunning

MalaCards organs/tissues related to Myocardial Stunning:

40
Heart, Endothelial, Neutrophil, Eye, Kidney, Cardiac Myocytes, Skeletal Muscle

Publications for Myocardial Stunning

Articles related to Myocardial Stunning:

(show top 50) (show all 1294)
# Title Authors PMID Year
1
Is timing everything? Therapeutic potential of modulators of cardiac Na(+) transporters. 54 61
12831348 2003
2
Pharmacological evidence for persistent activation of ATP-sensitive potassium channels in the early phase of reperfusion and its protective role against myocardial stunning. 54 61
8901700 1996
3
Do ATP-sensitive potassium channels play a role in myocardial stunning? 61 54
8534242 1995
4
ATP-sensitive potassium channels and myocardial preconditioning. 54 61
7646421 1995
5
Perioperative management in cardiovascular surgery. 61
33358388 2021
6
Trehalose preconditioning for transient global myocardial ischemia in rats. 61
33631668 2021
7
Involvement of non‑coding RNAs in the pathogenesis of myocardial ischemia/reperfusion injury (Review). 61
33576444 2021
8
Recurrent asymptomatic Takotsubo syndrome after 20 years: are we looking at the tip of the iceberg only? 61
32648481 2021
9
Bridging the Gap in a Rare Cause of Angina. 61
33737959 2021
10
Myocardial stunning and hibernation revisited. 61
33531698 2021
11
Salivary Gland Dysfunction in Patients with Chronic Heart Failure Is Aggravated by Nitrosative Stress, as Well as Oxidation and Glycation of Proteins. 61
33477706 2021
12
Cardiovascular Benefits of Extended-Time Nocturnal Hemodialysis. 61
32234001 2021
13
Stress cardiomyopathy following thyroidectomy in a premenopausal woman with thyroid cancer: case report and review of the literature. 61
33447569 2020
14
Left ventricular dyssynchrony and abnormalities in wall motion, assessed by gated-SPECT as ischemic auxiliary markers. 61
30515745 2020
15
Longer Dialysis Sessions Improve Cardiac Systolic Function by Reducing Myocardial Stunning. 61
32512217 2020
16
Response to: Loutradis et al. Longer Dialysis Sessions Improve Cardiac Systolic Function by Reducing Myocardial Stunning. 61
32890738 2020
17
Persistent cardiac arrest caused by profound hypokalaemia after large-dose insulin injection in a young man with type 1 diabetes mellitus: successful rescue with extracorporeal membrane oxygenation and subsequent ventricular assist device. 61
32628241 2020
18
Pathogenesis of Ventricular Arrhythmias and Its Effect on Long-Term Prognosis in Patients With Takotsubo Cardiomyopathy. 61
33262908 2020
19
Myocardial ischemia by radionuclide imaging and long-term outcomes after kidney transplantation. 61
32661630 2020
20
High magnesium dialysate does not improve intradialytic hemodynamics or abrogate myocardial stunning. 61
32844540 2020
21
Stress cardiomyopathy misinterpreted as ST-segment elevation myocardial infarction in a patient with aneurysmal subarachnoid hemorrhage: a case report. 61
32364523 2020
22
A Novel Disease Entity in Search of Its Own Identity - Takotsubo Syndrome. Is It Really "Cardiomyopathy"? 61
33693267 2020
23
Serum neprilysin levels are associated with myocardial stunning after ST-elevation myocardial infarction. 61
32615924 2020
24
Case report of successful peripheral veno-arterial extracorporeal membrane oxygenation in a patient with chronic type B aortic dissection. 61
32650702 2020
25
Non-invasive cardiovascular imaging for myocardial necrosis, viability, stunning and hibernation: evidence from an umbrella review encompassing 12 systematic reviews, 286 studies, and 201,680 patients. 61
32643896 2020
26
Takotsubo syndrome or myocardial stunning due to spasm of a non-obstructive left anterior descending coronary artery? 61
29923102 2020
27
Quantitative proteomic and phosphoproteomic profiling of ischemic myocardial stunning in swine. 61
32223553 2020
28
Better characterization of dipyridamole-induced myocardial stunning by systolic wall thickening. A gated perfusion SPECT study. 61
29951894 2020
29
Suppression of Superoxide-Hydrogen Peroxide Production at Site IQ of Mitochondrial Complex I Attenuates Myocardial Stunning and Improves Postcardiac Arrest Outcomes. 61
31939812 2020
30
The clinical usefulness of phase analysis in detecting coronary artery disease using dipyridamole thallium-201-gated myocardial perfusion imaging with a cadmium-zinc-telluride camera. 61
30171522 2020
31
Chemical chaperones improve the functional recovery of stunned myocardium by attenuating the endoplasmic reticulum stress. 61
31385408 2020
32
Temporary use of unusually high dose of catecholamine improved severe ventricular dysfunction associated with stunned myocardium without significant myocardial injury in a post cardiac surgical patient: A case report. 61
33059206 2020
33
Anesthesia Management for a Patient Undergoing Pulmonary Endarterctomy without Cardiopulmonary Bypass. 61
31793258 2019
34
Intradialytic exercise preconditioning: an exploratory study on the effect on myocardial stunning. 61
30590580 2019
35
Will Mary Jane Leave You Heartbroken? Marijuana Use and Risk of Takotsubo Cardiomyopathy. 61
31807375 2019
36
Paradoxical effect of testosterone supplementation therapy on cardiac ischemia/reperfusion injury in aged rats. 61
30930218 2019
37
Tyrosine nitration of mitochondrial proteins during myocardial ischemia and reperfusion. 61
31115776 2019
38
Renal Perfusion during Hemodialysis: Intradialytic Blood Flow Decline and Effects of Dialysate Cooling. 61
31053638 2019
39
Additional value of systolic wall thickening in myocardial stunning evaluated by stress-rest gated perfusion SPECT. 61
29119373 2019
40
Myocardial stunning by gated SPECT: An old tool reinvented in a stunning turn. 61
29139036 2019
41
Three-vessel myocardial bridging: A possible cause of myocardial stunning. 61
30031629 2019
42
Regional disparity in outcomes among patients hospitalized for Takotsubo cardiomyopathy in the United States✰. 61
30446395 2019
43
Perioperative ischaemic reperfusion injury and allograft function in the early post-transplantation period. 61
30919896 2019
44
High Dialysate Calcium Concentration is Associated with Worsening Left Ventricular Function. 61
30787343 2019
45
Association of Central Venous Oxygen Saturation Variability and Mortality in Hemodialysis Patients. 61
30522104 2019
46
A rare case of transient left ventricular apical ballooning syndrome following living donor liver transplantation: A case report and literature review. 61
30771626 2019
47
Novel Findings and Therapeutic Targets on Cardioprotection of Ischemia/ Reperfusion Injury in STEMI. 61
31692431 2019
48
Tight coronary artery stenosis and takotsubo syndrome triggered each other: Well-illustrated in a case. 61
29804797 2018
49
Heart Failure in End-Stage Kidney Disease: Pathophysiology, Diagnosis, and Therapeutic Strategies. 61
30413254 2018
50
Funny Lumps, Flaming Pheo, and a Broken Heart: A Rare Case of Pheochromocytoma. 61
30723645 2018

Variations for Myocardial Stunning

Expression for Myocardial Stunning

Search GEO for disease gene expression data for Myocardial Stunning.

Pathways for Myocardial Stunning

Pathways related to Myocardial Stunning according to GeneCards Suite gene sharing:

(show all 12)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.36 OPRD1 KNG1 EDN1 AGTR2 AGTR1 ADORA3
2
Show member pathways
12.27 KCNJ5 EDN1 AGTR1 ADORA2B
3 12.09 TNNI3 SLC9A1 EDN1 ADORA1
4
Show member pathways
12 TNNT2 TNNI3 EDN1 ACE
5
Show member pathways
11.78 TNNT2 TNNI3 SLC9A1 OPRD1 KNG1 AGTR2
6 11.63 OPRD1 KNG1 ADORA3 ADORA1
7 11.61 TNNT2 TNNI3 SLC9A1
8
Show member pathways
11.36 KNG1 AGTR2 AGTR1 ACE
9
Show member pathways
11.32 SOD3 SOD1 CAT
10
Show member pathways
11.18 ADORA3 ADORA2B ADORA1
11 11.1 EDN1 AGTR1 ADORA1 ACE
12 10.99 SOD3 SOD1 CAT

GO Terms for Myocardial Stunning

Cellular components related to Myocardial Stunning according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.97 SOD3 SOD1 SLC9A3R2 SLC9A1 SERPINC1 KNG1
2 integral component of plasma membrane GO:0005887 9.87 SLC9A1 OPRD1 AGTR2 AGTR1 ADORA3 ADORA2B
3 plasma membrane GO:0005886 9.47 SOD1 SLC9A3R2 SLC9A1 SERPINC1 OPRD1 KNG1
4 troponin complex GO:0005861 9.26 TNNT2 TNNI3
5 cardiac myofibril GO:0097512 9.16 TNNT2 TNNI3
6 cardiac Troponin complex GO:1990584 8.96 TNNT2 TNNI3

Biological processes related to Myocardial Stunning according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 10.01 OPRD1 KNG1 EDN1 AGTR2 AGTR1 ADORA3
2 inflammatory response GO:0006954 9.92 KNG1 AGTR2 AGTR1 ADORA3 ADORA1
3 response to hypoxia GO:0001666 9.81 SOD3 EDN1 CAT ADORA1
4 cellular response to oxidative stress GO:0034599 9.8 SOD3 SOD1 CAT
5 kidney development GO:0001822 9.73 CAT AGTR2 AGTR1 ACE
6 adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway GO:0007193 9.72 OPRD1 EDN1 ADORA1
7 regulation of muscle contraction GO:0006937 9.65 TNNT2 TNNI3
8 regulation of pH GO:0006885 9.65 SLC9A1 EDN1
9 response to reactive oxygen species GO:0000302 9.64 SOD1 CAT
10 response to muscle stretch GO:0035994 9.64 SLC9A1 EDN1
11 response to copper ion GO:0046688 9.63 SOD3 SOD1
12 superoxide anion generation GO:0042554 9.63 SOD1 EDN1
13 positive regulation of renal sodium excretion GO:0035815 9.62 EDN1 AGTR2
14 negative regulation of blood coagulation GO:0030195 9.61 KNG1 EDN1
15 removal of superoxide radicals GO:0019430 9.61 SOD3 SOD1
16 positive regulation of systemic arterial blood pressure GO:0003084 9.6 ADORA1 ACE
17 negative regulation of ATPase activity GO:0032780 9.59 TNNT2 TNNI3
18 negative regulation of hormone secretion GO:0046888 9.58 EDN1 ADORA1
19 angiotensin-activated signaling pathway GO:0038166 9.58 AGTR2 AGTR1
20 relaxation of vascular smooth muscle GO:0060087 9.57 SOD1 ADORA1
21 regulation of cardiac muscle contraction by calcium ion signaling GO:0010882 9.56 TNNI3 SLC9A1
22 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.54 AGTR1 ACE
23 regulation of blood vessel diameter GO:0097746 9.54 AGTR2 AGTR1 ACE
24 regulation of vasoconstriction GO:0019229 9.5 EDN1 AGTR1 ACE
25 hemoglobin metabolic process GO:0020027 9.49 CAT AHSP
26 response to ozone GO:0010193 9.48 EDN1 CAT
27 renin-angiotensin regulation of aldosterone production GO:0002018 9.46 AGTR2 AGTR1
28 regulation of blood pressure GO:0008217 9.46 SOD1 EDN1 AGTR2 ACE
29 heart contraction GO:0060047 9.43 TNNI3 SOD1 ACE
30 adenosine receptor signaling pathway GO:0001973 9.13 ADORA3 ADORA2B ADORA1
31 regulation of sensory perception of pain GO:0051930 8.92 SLC9A1 OPRD1 EDN1 ADORA1

Molecular functions related to Myocardial Stunning according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.91 OPRD1 AGTR2 AGTR1 ADORA3 ADORA2B ADORA1
2 protein phosphatase 2B binding GO:0030346 9.4 SOD1 SLC9A1
3 superoxide dismutase activity GO:0004784 9.37 SOD3 SOD1
4 angiotensin type II receptor activity GO:0004945 9.32 AGTR2 AGTR1
5 troponin C binding GO:0030172 9.26 TNNT2 TNNI3
6 bradykinin receptor binding GO:0031711 9.16 AGTR1 ACE
7 antioxidant activity GO:0016209 9.13 SOD3 SOD1 CAT
8 G protein-coupled adenosine receptor activity GO:0001609 8.8 ADORA3 ADORA2B ADORA1

Sources for Myocardial Stunning

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....